News

Detecting heart failure in its earliest stages has long been a challenge for clinicians, particularly when the cause is a rare and often misdiagnosed protein…

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study…

Anumana, a Massachusetts-based artificial intelligence (AI) company co-founded by nference and Mayo Clinic, has received U.S. Food and Drug Administration (FDA)…

Anumana has received FDA approval for its ECG-AI algorithm designed to support the diagnosis of cardiac amyloidosis at the point of care. This makes it the first…

Anumana, a leader in cardiovascular AI, announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI algorithm for cardiac amyloidosis (CA) – the first…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI™…

Swelling and fluid retention are common symptoms for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). This condition causes the heart muscle to…

In Las Vegas, Nevada, United States, DelveInsight's assessment reveals that globally, there are 10 key companies actively developing treatment therapies for AL…

NICE(UK): Acoramidis can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in…

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.